The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic.

Change log
Frankell, Alexander M 
Jammula, SriGanesh 
Li, Xiaodun 
Contino, Gianmarco 
Killcoyne, Sarah 

Esophageal adenocarcinoma (EAC) is a poor-prognosis cancer type with rapidly rising incidence. Understanding of the genetic events driving EAC development is limited, and there are few molecular biomarkers for prognostication or therapeutics. Using a cohort of 551 genomically characterized EACs with matched RNA sequencing data, we discovered 77 EAC driver genes and 21 noncoding driver elements. We identified a mean of 4.4 driver events per tumor, which were derived more commonly from mutations than copy number alterations, and compared the prevelence of these mutations to the exome-wide mutational excess calculated using non-synonymous to synonymous mutation ratios (dN/dS). We observed mutual exclusivity or co-occurrence of events within and between several dysregulated EAC pathways, a result suggestive of strong functional relationships. Indicators of poor prognosis (SMAD4 and GATA4) were verified in independent cohorts with significant predictive value. Over 50% of EACs contained sensitizing events for CDK4 and CDK6 inhibitors, which were highly correlated with clinically relevant sensitivity in a panel of EAC cell lines and organoids.

Adenocarcinoma, Biomarkers, Tumor, Cohort Studies, DNA Copy Number Variations, Esophageal Neoplasms, Exome, Female, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Genomics, Humans, Male, Mutation
Journal Title
Nature Genetics
Conference Name
Journal ISSN
Volume Title
Springer Nature
All rights reserved
Cancer Research UK (C14303/A17197)
Medical Research Council (MC_UU_12022/2)
OCCAMS was funded by a Programme Grant from Cancer Research UK (RG66287), and the laboratory of R.C.F. is funded by a Core Programme Grant from the Medical Research Council. We thank the Human Research Tissue Bank, which is supported by the UK National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre, from Addenbrooke’s Hospital. Additional infrastructure support was provided from the Cancer Research UK–funded Experimental Cancer Medicine Centre.